KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Accumulated Expenses (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Accumulated Expenses for 12 consecutive years, with $3.5 million as the latest value for Q3 2024.

  • On a quarterly basis, Accumulated Expenses fell 60.47% to $3.5 million in Q3 2024 year-over-year; TTM through Sep 2024 was $3.5 million, a 60.47% decrease, with the full-year FY2023 number at $175000.0, down 98.37% from a year prior.
  • Accumulated Expenses was $3.5 million for Q3 2024 at Palvella Therapeutics, down from $5.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $19.7 million in Q3 2021 to a low of $175000.0 in Q4 2023.
  • A 5-year average of $8.5 million and a median of $7.7 million in 2020 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 170.67% in 2021, then tumbled 98.37% in 2023.
  • Palvella Therapeutics' Accumulated Expenses stood at $7.7 million in 2020, then skyrocketed by 117.77% to $16.8 million in 2021, then crashed by 36.17% to $10.7 million in 2022, then crashed by 98.37% to $175000.0 in 2023, then skyrocketed by 1873.14% to $3.5 million in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Accumulated Expenses are $3.5 million (Q3 2024), $5.4 million (Q2 2024), and $4.2 million (Q1 2024).